Citations

Clear

17 citation(s) found for "Li, Yunfeng".

Caregiver experiences after the death of a person with dementia with Lewy bodies: A mixed-methods analysis
Armstrong, Melissa J. , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Sovich, Kaitlin , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M. , Paulson, Henry L. , Fields, Julie A. , Lunde, Angela , Manning, Carol A. , Taylor, Angela , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M , Lunde, Angela M , Boeve, Brad , Baker, Zachary G , Paulson, Henry L , Armstrong, Melissa J , Wollney, Easton N. , Li, Zhigang , Galvin, James E. , Boeve, Bradley F.

Mayo Clinic

Journal of Alzheimer’s Disease | August 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877251365218 | PMID 40808538 Get It

Background Dementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences. Objective To investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach. Methods Dyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews. Results Seventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal. Conclusions The finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB. Trial registration information NCT04829656 (submitted 2021-03-22).
PFKFB3 controls acinar IP3R-mediated Ca2+ overload to regulate acute pancreatitis severity
Chen, Shengchuan , Jin, Yuepeng , Liu, Siying , Liu, Zhu, Shi, Fengyu, Xie, Lifen, Guo, Panpan , Ergashev, Akmal , Yao, Haiping , Huang, Chaohao , Zhang, Baofu , Wu, Lijun, Sun, Hongwei , Chen, Siming , Yu, Zhengping , Tolosa, Ezequiel J. , Fernández-Zapico, Martín E. , Ma, Feng , Cannon, Andrew C, Zhang, Tan , Li, Liang , Shi, Fengyu, Guo, Panpan , Cannon, Andrew , Wu, Lijun, Chen, Siming, Shan, Yunfeng , Liu, Jianghuai , Chen, Gang

Mayo Clinic

JCI Insight | May 23, 2024 | Volume: 9 | Issue: 13 | Pages: No page available

10.1172/jci.insight.169481 | PMID 38781030 Get It

Acute pancreatitis (AP) is among the most common hospital gastrointestinal diagnoses; understanding the mechanisms underlying the severity of AP is critical for development of new treatment options for this disease. Here, we evaluate the biological function of phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in AP pathogenesis in 2 independent genetically engineered mouse models of AP. PFKFB3 was elevated in AP and severe AP (SAP), and KO of Pfkfb3 abrogated the severity of alcoholic SAP (FAEE-SAP). Using a combination of genetic, pharmacological, and molecular studies, we defined the interaction of PFKFB3 with inositol 1,4,5-trisphosphate receptor (IP3R) as a key event mediating this phenomenon. Further analysis demonstrated that the interaction between PFKFB3 and IP3R promotes FAEE-SAP severity by altering intracellular calcium homeostasis in acinar cells. Together, our results support a PFKFB3-driven mechanism controlling AP pathobiology and define this enzyme as a therapeutic target to ameliorate the severity of this condition.
Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation
Shi, Zhehao , Jin, Bin , Ye, Wen , Wang, Luhui , Zhang, Sina , Zheng, Jiuyi , Lin, Zixia, Chen, Bo, Liu, Fangting , Zhang, Baofu , Ding, Xiwei , Shan, Yunfeng , Yu, Zhengping , Wang, Yi , Chen, Jicai , Roberts, Lewis R. , Chen, Gang , Chen, Gang , Roberts, Lewis R , Li, Zhiming , Liu, Fangting, Yang, Zhen Fan , Chen, Qiang

Mayo Clinic

Clinical and Translational Medicine | June 20, 2023 | Volume: 13 | Issue: 6 | Pages: No page available

10.1002/ctm2.1300 | PMID 37337470 Get It

AbstractBackgroundFerroptosis is an important iron‐dependent form of cell death in hepatocellular carcinoma (HCC). Sorafenib, a potent ferroptosis inducer, is used to treat advanced HCC but its efficacy is limited by the development of drug resistance.MethodsThe effects of DUXAP8 expression on HCC progression were evaluated by TCGA database, Kaplan‐Meier analysis, and in situ hybridization analysis. Sorafenib resistant HCC cell lines were modeled in vitro to study the regulation of DUXAP8 on ferroptosis in HCC induced by sorafenib. We used RNA pull‐down, immunofluorescence assays, acyl‐biotinyl exchange assay and mass spectrometry analysis to assess the molecular mechanism of ferroptosis regulation by DUXAP8. Syngeneic subcutaneous and orthotopic CDX models were used to assess whether DUXAP8 inhibition improves HCC in vivo.ResultsLncRNA DUXAP8, which is highly expressed in liver cancer and associated with poor prognosis, contributes to sorafenib resistance through suppression of ferroptosis. In vitro tests revealed that DUXAP8 reduced the sensitivity of HCC to sorafenib‐induced ferroptosis by acting on SLC7A11, a subunit of the amino acid antiporter system xc‐. DUXAP8 facilitates SLC7A11 palmitoylation and impedes its lysosomal degradation, thereby enhancing SLC7A11 action and suppressing ferroptosis. RNA pull‐down and immunofluorescence assays confirmed that DUXAP8 decreased membrane translocation and promoted sorting of de‐palmitoylated SLC7A11 to lysosomes by binding of DUXAP8 to SLC7A11. In addition, mass spectrometric analysis found that the Cys414 residue of SLC7A11 might be the predominant mutant site responsible for molecular masking of SLC7A11 lysosomal sorting. Further, the antitumor effect of DUXAP8 knockdown was verified in orthotopic and subcutaneous CDX models.ConclusionsOur findings suggest that a novel translational strategy combining sorafenib with DUXAP8 silencing to overcome drug resistance may improve treatment efficacy in patients with advanced HCC.
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
Patnaik, Amita , Tan, Winston , Jahchan, Nadine S. , Pierce, Kristen J. , Li, Yunfeng , Reyno, Len, Chamberlain, Marc C. , Hamilton, Erika , Winer, Ira Seth , Hubbard, Joleen M. , Schenk, Erin L. , Sonbol, Mohamad Bassam , Pierce, Kristen

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2648-2648

10.1200/jco.2022.40.16_suppl.2648 Get It

2648 Background: To characterize the safety and tolerability of PY314, an immunosuppressive macrophage depleting antibody, as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including subject’s refractory to checkpoint inhibitors if approved for that indication. Methods: Two were evaluated in subjects with advanced solid tumors, single agent PY314 and PY314 in combination with 200 mg of pembrolizumab using a 3+3 dose escalation study design. Dosing was intravenous and administered once every 3-weeks, a defined cycle. Disease assessment by RECIST 1.1 was performed every 6 weeks. Each stratum included 4 dose levels of PY314 (1, 3, 10, and 20 mg/kg). Pharmacokinetics were evaluated at specified time points. Archival tumor tissue was analyzed for TREM2 expression by immunohistochemistry. Based on preclinical evaluation of TREM2 expression, HR+ HER2- and triple negative breast cancer, colorectal cancer, renal cell cancer, non-small cell lung cancer and gynecologic cancers were studied. Results: 28 subjects (median age 60 years [range 26-76], 22 females and 6 ) with an ECOG PS <2 were enrolled and all, but one was (1 subject withdrew consent after dosing). 15 subjects were treated with single agent PY314 and 13 were treated with the combination. No infusion-related reactions, dose limiting toxicities, suspected unexpected serious adverse reactions or high-grade treatment related adverse events (TRAEs) that resulted in treatment discontinuance was seen. 12 subjects experienced at least one TRAE, and in all but one subject, these were low grade. One subject experienced a treatment-related immune system disorder. serious adverse events, all unrelated to treatment. TREM2 expression in archival tumor ranged from 0.0-20%. PY314 pharmacokinetics were linear, dose proportional, unaffected by concomitant pembrolizumab and with a half-life of 8-9 days. Best radiographic response was stable disease seen in 11 subjects (39.3%) ranging in duration from 9-42 weeks. 6 subjects with stable disease have progressed and 5 remain on treatment. Conclusions: PY314 was well tolerated and has an excellent safety profile both as a single agent and in combination with pembrolizumab. A recommended dose for expansion was derived and enrollment in five prespecified cancers is ongoing. Clinical trial information: 04691375.
Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki, Furuya, Hideki , Furuya, Hideki , Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki

Mayo Clinic

Cancer Biomarkers | September 7, 2021 | Volume: 33 | Issue: 1 | Pages: 151-157

10.3233/cbm-210221 | PMID 34511488 Get It

BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80–0.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.
Contribution of Ictal Source Imaging for Localizing Seizure Onset Zone in Patients With Focal Epilepsy
Yang, Lin , Lu, Yunfeng , Brinkmann, Benjamin H. , Nelson, Cindy, He, Bin , Ye, Shuai, Kucewicz, Michał T. , Brinkmann, Benjamin, Sohrabpour, Abbas , He, Bin , Brinkmann, Benjamin H , Ye, Shuai , Nelson, Cindy, Worrell, Gregory A.

Mayo Clinic

Neurology | October 24, 2020 | Volume: 96 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000011109 | PMID 33097598 Get It

Induction and Prevention of Gastric Cancer with Combined Helicobacter Pylori and Capsaicin Administration and DFMO Treatment, Respectively
Aziz, Faisal , Xin, Mingxia, Gao, Yunfeng , Chakroborty, Abhijit, Monts, Josh , Monson, Kjersten, Bode, Ann M. , Khan, Imran , Dong, Zigang

Mayo Clinic

Cancers | April 1, 2020 | Volume: 12 | Issue: 4 | Pages: 816

10.3390/cancers12040816 | PMID 32231118 Get It

Gastric cancer risk evolves over time due to environmental, dietary, and lifestyle changes, including Helicobacter pylori (H. pylori) infection and consumption of hot peppers (i.e., capsaicin). H. pylori infection promotes gastric mucosal injury in the early phase of capsaicin exposure. This relationship suggests a need to investigate the mechanism of how both H. pylori infection and capsaicin contribute to gastric inflammation and lead to gastric cancer. C57-Balb/c mice were infected with the H. pylori (SS1) strain and then fed capsaicin (0.05% or 0.2 g/kg/day) or not. Consequently, tumor size and phenotype were analyzed to determine the molecular mechanism driving the shift from gastritis to stomach cancer. Moreover, we used 2-difluoromethylornithine (DFMO) in mice to prevent gastric tumorigenesis by reducing inflammation and promoting recovery of disease-free stasis. This study provides evidence showing that a combination of H. pylori infection and capsaicin consumption leads to gastric carcinogenesis mediated through interleukin-6 (IL-6) stimulation with an incidence rate of 50%. The anti-inflammatory role of DFMO highlights the injurious effect of inflammation in gastric cancer development and the need to reduce gastric inflammation for cancer prevention by inhibiting IL-6. Accordingly, preventive measures such as reduced capsaicin consumption, H. pylori clearance, and DFMO treatment may lessen gastric cancer incidence.
Induction and prevention of gastric cancer with combined Helicobacter pylori and capsaicin administration and DFMO treatment, respectively
Xin, Mingxia, Gao, Yunfeng , Monts, Josh , Monson, Kjersten, Wang, Qiushi , Bode, Ann M. , dong, zigang , Dong, Zigang , Aziz, Faisal , dong, zigang

Mayo Clinic

No container title available | January 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.21633/v1 Get It

Abstract Background: Gastric cancer risk evolves over time due to environmental, dietary, and lifestyle changes including Helicobacter pylori (H. pylori) infection and consumption of hot peppers (i.e. capsaicin). H. pylori infection promotes gastric mucosal injury in the early phase of capsaicin exposure. In addition, capsaicin consumption is reported to suppress immune function and increase host susceptibility to microbial infection. This relationship suggests a need to investigate the mechanism of how both H. pylori infection and capsaicin contribute to gastric inflammation and lead to gastric cancer. No previous experimental animal models have been developed to study this dual association. Here we developed a series of mouse models that progress from chronic gastritis to gastric cancer. C57-Balb/c mice were infected with the H. pylori (SS1) strain and then fed capsaicin (0.05% or 0.2g/kg/day) or not. Consequently, we investigated the association between H. pylori infection and capsaicin consumption during the initiation of gastric inflammation and the later development of gastric cancer. Tumor size and phenotype were analyzed to determine the molecular mechanism driving the shift from gastritis to stomach cancer. Gastric carcinogenesis was also prevented in these models using the ornithine decarboxylase inhibitor DFMO (2-difluoromethylornithine). Results: This study provides evidence showing that a combination of H. pylori infection and capsaicin consumption leads to gastric carcinogenesis. The transition from chronic gastritis to gastric cancer is mediated through interleukin-6 (IL-6) stimulation with an incidence rate of 50%. However, this progression can be prevented by treating with anti-inflammatory agents. In particular, we used DFMO to prevent gastric tumorigenesis by reducing inflammation and promoting recovery of disease-free stasis. The anti-inflammatory role of DFMO highlights the injurious effect of inflammation in gastric cancer development and the need to reduce gastric inflammation for cancer prevention. Conclusions: Overall, these mouse models provide reliable systems for analyzing the molecular mechanisms and synergistic effects of H. pylori and capsaicin on human cancer etiology. Accordingly, preventive measures like reduced capsaicin consumption, H. pylori clearance, and DFMO treatment can lessen gastric cancer incidence. Lastly, anti-inflammatory agents like DFMO can play important roles in prevention of inflammation-associated gastric cancer.
Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia
Gu, Zhaohui , Moore, Ian, Hagiwara, Kohei , Gingras, S., Berns, Hartmut , Payne-Turner, Debbie , Hill, Ashley, Pounds, Stanley , Pei, Deqing, Dai, Yunfeng , Reshmi, Shalini C. , Foster, Julie Gastier, Raetz, Elizabeth A. , Borowitz, Michael J., Carroll, William L. , McKay, Patrick Zweider, Mattano, Leonard A. , Maloney, Kelly W. , Rambaldi, Alessandro , Radich, Jerald P. , Minden, Mark D. , Rowe, Jacob M. , Luger, Selina M. , Litzow, Mark R. , Tallman, Martin S. , Recevskis, Janis, Zhang, Yanming , Kohlschmidt, Jessica, Bloomfield, Clara D. , Konopleva, Marina , Evans, William E. , Paietta, Elisabeth , Relling, Mary V. , Zhang, Jinghui , Rambaldi, Alessandro , Pounds, Stanley B , Churchman, Michelle L. , Roberts, Kathryn G. , Zhou, Xin , Nakitandwe, Joy , Pelletier, S. William , Iacobucci, Ilaria , Shi, Lei Gang , Cheng, Cheng , Qu, Chunxu , Devidas, Meenakshi , Wood, Brent L. , Rabin, Karen R. , Spinelli, Orietta , Bhatia, Ravi , Mrózek, Krzysztof , Stock, Wendy , Kornblau, Steven M. , Kantarjian, Hagop M. , Jeha, Sima , Pui, Ching-Hon , Yang, Jun J.J. , Downing, James R. , Loh, Mignon L. , Hunger, Stephen P. , Mullighan, Charles G.

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 565-565

10.1182/blood-2018-99-111219 Get It

Abstract Introduction B progenitor acute lymphoblastic leukemia (B-ALL) is a leading cause of childhood cancer death. Many chimeric genes have been identified and led to a refined classification of B-ALL and tailored therapies. Still, up to 30% of B-ALL cannot be classified into established subtypes, and the outcome for many is poor. Methods To identify novel subtypes of B-ALL, we performed integrative genomic analysis including transcriptome sequencing (RNA-seq) of 1,988 cases from St. Jude, Children's Oncology Group and adult cooperative group studies and analyzed chromosomal rearrangements, gene-expression profiles (GEP), somatic mutations and chromosome-level copy-number alterations. Cases lacking known or putative subtype-defining alterations underwent whole genome sequencing. Effects on proliferation and transformation of novel lesions were assessed by retroviral expression in cell lines and point-mutation knock-in mice using CRISPR/Cas9 genome editing. Results Using integrated genetic alterations and gene expression profiling, we classified 23 B-ALL subtypes (Table and Figure). Three groups included cases with similar GEP as canonical subtypes (ETV6-RUNX1, KMT2A-rearranged, and ZNF384-rearranged), but lacking the expected drivers (e.g., ETV6-RUNX1-like, n=42). Eighteen cases (0.9%) had rearrangements of BCL2, MYC and/or BCL6 showing a distinct GEP; they were mostly adults (n=16) with very poor outcome. These alterations, rarely seen in ALL, are identical to those observed in "double/triple hit" lymphoma, and are of pre-B immunophenotype. Eight cases with tightly clustered GEP comprised a novel subtype defined by IKZF1 N159Y missense mutation. N159Y is in the DNA-binding domain of IKZF1, and is known to perturb IKZF1 function, with distinct nuclear mislocalization and induction of aberrant intercellular adhesion. We identified two subtypes with distinct GEP characterized by PAX5 alterations. One, herein termed PAX5 altered (PAX5alt), comprised 148 (7.4%) cases, was characterized by diverse PAX5 alterations including rearrangements (n=57), sequence mutations (n=46) and/or focal intragenic amplifications (n=8). These PAX5 alterations were found in 73.6% of PAX5alt cases and different alteration types were mutually exclusive. Other PAX5 alterations, including deletions and large-scale amplifications were also assessed using SNP array, but were not enriched in the PAX5alt group. Clinically, PAX5alt pediatric and adult patients had favorable (96.8±3.2%) and intermediate (42.1±10.2%) 5-year overall survival (OS), respectively. The other GEP distinct subtype comprised 44 cases, all with PAX5 P80R missense mutations. In 30 of these cases, PAX5 P80R was homozygous due to deletion of the wild-type (WT) PAX5 allele or copy-neutral loss of heterozygosity. Of the other 14 cases with heterozygous PAX5 P80R mutations, 13 had a second frameshift (n=7), nonsense (n=2) or deleterious missense (n=4) PAX5 mutation. Four of the remaining 1,944 cases also had the PAX5 P80R mutation, but all were heterozygous with preservation of a WT PAX5 allele, consistent with the notion that homozygous or compound heterozygous PAX5 P80R mutation is the hallmark of this subtype. Adult PAX5 P80R cases (n=14) showed better 5-year OS (61.9±13.4%) than those in PAX5alt subtype (42.1±10.2%). To examine the effects of PAX5 P80R on B-cell maturation, WT PAX5, PAX5 P80R, V26G and P34Q were expressed in Pax5-/- lineage-depleted bone marrow cells. Expression of WT PAX5, PAX5 V26G and P34Q resulted in near complete rescue of B cell differentiation; however, expression of PAX5 P80R blocked the differentiation at the pre-pro-B stage of B-cell maturation. Further, Pax5 P80R heterozygous or homozygous mice developed pre-B-ALL with a median latency of 166 and 87 days, respectively, with heterozygous mice acquiring alterations on the second allele. In contrast, Pax5+/- mice, and those harboring G183S mutation observed in familial leukemia, do not spontaneously develop B-ALL. Conclusions These results show the utility of transcriptome sequencing in defining subtypes and founding genetic alterations in B-ALL, provide a revised taxonomy of the disease across the age spectrum, and reinforce the central role of PAX5 as a checkpoint in B lymphoid maturation and leukemogenesis. Disclosures McKay: ImmunoGen Inc.: Employment. Tallman:Orsenix: Other: Advisory board; AROG: Research Funding; BioSight: Other: Advisory board; Cellerant: Research Funding; AbbVie: Research Funding; Daiichi-Sankyo: Other: Advisory board; ADC Therapeutics: Research Funding. Stock:Jazz Pharmaceuticals: Consultancy. Konopleva:Stemline Therapeutics: Research Funding. Relling:Shire Pharmaceuticals: Research Funding. Mullighan:Cancer Prevention and Research Institute of Texas: Consultancy; Amgen: Honoraria, Speakers Bureau; Abbvie: Research Funding; Loxo Oncology: Research Funding; Pfizer: Honoraria, Research Funding, Speakers Bureau.